Treatment of Moderate Erosive Gastritis

Initial Treatment Approach

The American College of Gastroenterology recommends starting with a standard-dose proton pump inhibitor (PPI) once daily, taken 30-60 minutes before the first meal of the day, for optimal acid suppression in patients with moderate erosive gastritis 1, 2
The timing of PPI administration is critical, and PPIs must be taken before meals to coincide with postprandial peak in active proton pumps for maximum efficacy in patients with erosive gastritis 3, 1
The American Gastroenterological Association recommends avoiding twice-daily dosing as initial therapy for erosive gastritis, as it is not FDA-approved and lacks strong evidence support while increasing costs unnecessarily 1
Treatment duration should be 4-8 weeks for initial healing of erosive lesions in patients with moderate erosive gastritis 1

The American College of Gastroenterology recommends that patients with healed erosive gastritis require continuous daily PPI therapy indefinitely to prevent recurrence of erosive disease 2
Daily maintenance dosing is essential, and on-demand or intermittent therapy is explicitly contraindicated for patients with documented erosive gastritis, as recurrence rates are unacceptably high with less-than-daily dosing 1, 2
Maintenance therapy should be titrated to the lowest effective dose based on symptom control, but daily dosing must be maintained in patients with erosive gastritis 1
PPIs are dramatically superior to H2-receptor antagonists for both healing and maintenance, with patients on H2RAs being up to twice as likely to have recurrent disease in the context of erosive gastritis 2

Moderate erosive gastritis requires continuous daily PPI therapy after initial healing, analogous to Los Angeles grade B erosive esophagitis 1, 2
The American Gastroenterological Association recommends not attempting step-down therapy or de-prescribing in patients with documented erosive disease, as this leads to high recurrence rates 4, 5, 1

Implement concurrent lifestyle modifications, including avoiding recumbency for 2-3 hours after meals, limiting dietary fat intake to less than 45 grams per day, avoiding individual trigger foods, smoking, and excessive alcohol consumption, and treating conditions that may exacerbate gastric acid exposure in patients with erosive gastritis 2

Routine endoscopic monitoring to assess disease progression is not recommended once healing is achieved in patients with erosive gastritis 2
The indication for long-term PPI therapy should be clearly documented in the medical record for patients with erosive gastritis 1

Never use on-demand or intermittent PPI therapy for patients with documented erosive gastritis, as this approach is only appropriate for non-erosive reflux disease and leads to high recurrence rates of erosive lesions 1, 2
Do not substitute H2-receptor antagonists for maintenance therapy, as they are significantly less effective than PPIs for preventing recurrence in patients with erosive gastritis 2
Do not prescribe twice-daily PPI dosing as initial therapy, as it lacks FDA approval and proven benefit for erosive gastritis while increasing costs 1
Do not discontinue PPIs in patients with healed erosive gastritis without understanding that recurrence is highly likely and continuous therapy is the standard of care 4, 5, 2

Discontinuation of NSAIDs, aspirin, corticosteroids, and oral bisphosphonates is recommended as they are gastric mucosal irritants, according to guidelines from The Lancet Oncology and Circulation 6, 7

For NSAID-induced erosive gastritis, continuation of PPI therapy and consideration of discontinuing the NSAID or switching to acetaminophen is advised, as suggested by Circulation 7

Endoscopy is the most effective diagnostic examination for gastric erosions and should be performed in patients who present with alarm symptoms, have persistent symptoms despite empirical therapy, or are older than the locally defined age threshold for gastric cancer risk. 8
Testing for Helicobacter pylori is mandatory in all patients with gastric erosions; preferred methods include the ^13C urea breath test, stool antigen test, or a locally validated serologic assay with ≥90 % sensitivity and specificity. 8
A complete blood count should be obtained to evaluate for anemia that may result from chronic gastrointestinal blood loss in patients with erosive disease. 9

In patients who test positive for H. pylori, eradication therapy is essential because it prevents disease progression and markedly reduces the risk of recurrence of erosive gastritis. 8

Routine repeat endoscopy is not recommended after successful healing of erosions; however, it should be performed if symptoms persist or worsen despite adequate proton‑pump inhibitor (PPI) therapy. 8
Repeat endoscopy is also indicated when new alarm features develop, such as dysphagia, unexplained weight loss, persistent vomiting, or objective evidence of gastrointestinal bleeding. [8][9]

Failure to test for H. pylori is a common error; because infection is a major determinant of disease evolution and treatment success, omission of testing can compromise patient outcomes. 8